Healthcare, Pharmaceuticals and Biotech

Kroll helps organizations in the healthcare, pharmaceuticals and biotechnology sectors address complex business challenges related to governance, risk and transparency.

Pharmaceutical, healthcare, biotech and medical device companies face a challenging, competitive health landscape. Pricing pressures, scientific breakthroughs, expanding demand for healthcare access and emerging digital and analytic capabilities push companies to explore unconventional business models and build value-based customer relationships.

Underpinning these dynamics is the uncertainty created by a post-COVID-19 environment. The implications have been far-reaching and will likely impact the entire life science ecosystem. While companies need to be aware of the risks to their organization, Kroll understands the complexity of these challenges and works with clients worldwide to drive progress, navigate new opportunities and manage risk.

Our life sciences specialists bring practical, in-depth experience to healthcare and life sciences companies, including consumer health, medical devices, diagnostics and pharmaceuticals. We help our clients address their most pressing challenges in in the areas of valuation, expert services, investigations, cyber risk, corporate finance, security, restructuring, legal and business solutions, data analytics, due diligence and regulatory compliance.

Please join us June 21-24 for Kroll’s Life Sciences week. We will bring together our leading experts and industry leaders to set the roadmap for a new era where pharma, patients, providers and society are united in their efforts of greater value.

We will provide insights for pharmaceutical and life sciences professionals on operational risk, compliance, supply chain, health and safety and technology, including:

• “Deep-dive interviews” with industry leaders demonstrating examples on their approach
• Inherent  risks impacting the industry   
• Case studies on how the life science industry has managed to adapt to market changes
• Commentary on the latest regulation, technology developments and industry trends
• Panel discussions that cover the most important challenges due to the impact of COVID-19